Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: COVID-19, Healthy
Interventions: Optate, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions: Ketorolac Tromethamine 30 MG/ML, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Interventions: Allopregnanolone, Placebo; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 55 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more

Conditions: Tularaemia
Interventions: Placebo, Undiluted Francisella tularensis live attenuated vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Moderate-to-Severe Asthma
Interventions: Anti-GM-CSF Monoclonal Antibody 400mg, Placebo; Biological · Other
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more

Conditions: COVID-19
Interventions: BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more

Conditions: Craniosynostosis
Interventions: Amicar (ε-aminocaproic acid), normal saline; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Months to 36 Months
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Full-thickness Rotator Cuff Tear
Interventions: Arthroscopic Rotator Cuff Repair, Ropivacaine, Saline; Procedure · Drug
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Rheumatoid Arthritis
Interventions: Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: GBS Disease, Streptococcus Agalactiae
Interventions: GBS trivalent vaccine, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Prosthetic-joint Infection
Interventions: PLG0206, Placebo; Drug
Lead sponsor: Peptilogics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Pensacola, Florida • Sarasota, Florida • Tamarac, Florida + 14 more

Conditions: Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions: Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr; Drug
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Pain, Migraine Disorders
Interventions: PF-04427429, Normal saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Miami, Florida • Dallas, Texas

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myocardial Infarction, Moderate Renal Impairment
Interventions: CSL_112, Placebo; Biological · Other
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Allogeneic Mesenchymal Precursor Cells, Normal Saline; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 20
States / cities: Anniston, Alabama • Gilbert, Arizona • El Cajon, California + 17 more

Conditions: Prostate Cancer
Interventions: vaccine vehicle only, DC/LNCaP; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Failure, Acute, Renal Replacement Therapy
Interventions: Sodium bicarbonate, Normal saline, Bicarbonate, Placebo; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Late Onset Pompe Disease
Interventions: ABX1100 injection for IV infusion, Placebo injection for IV infusion; Drug
Lead sponsor: Aro Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Orange, California • St Louis, Missouri • Fairfax, Virginia

Conditions: Prostatic Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 29
States / cities: Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more

Search by objective public record fields.

A Nasal Treatment for COVID-19

IV Ketorolac on Platelet Function Post-Cesarean Delivery

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Phase II Tularemia Vaccine Comparison

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Efficacy of Amicar for Children Having Craniofacial Surgery

Neural Circuit Effects of Ketamine in Depression

Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks

CD40L Antagonism in Rheumatoid Arthritis (RA)

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms